AnalystBook Research · Company Intelligence

Decoy Therapeutics Inc.

DCOYNasdaq

Built from Decoy Therapeutics Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Net income decreased 124.5% to ($12.5M), while Operating cash flow decreased 6.7% to ($4.8M).

The read at a glance✓ Audited against SEC data
  • ScaleFY2025 revenue N/AWatch
  • ProfitabilityNet income ($12.5M)Watch
  • Cash generationFree cash flow ($4.8M)Note
  • AccountingNo applicable forensic screenNote
  • Insiders2 buys; 1 sells in 365 daysOK
  • CapitalComparable payout data unavailableNote

Business

Decoy Therapeutics Inc.: We have never generated revenue from product sales, and all of our potential product candidates are currently in the preclinical stage, and we may continue to incur significant losses for the foreseeable future and never generate revenue from product sales.

Leadership changes

From Decoy Therapeutics Inc.'s own filings, the day they're filed.

  • Barbara Hibner · Chief Scientific Officer · appointmenteff. 2025-11-12
  • Frederick E. Pierce · Directors · departureeff. 2025-11-12
  • Mark Rosenblum · Chief Executive Officer · departureeff. 2025-11-12

Latest filings

  • 10-Q · Quarterly report2026-08-12
  • DEF 14A · Annual proxy (pay & governance)2026-08-04
  • 8-K · Company announcement2026-07-15
  • 8-K · Company announcement2026-06-29
  • DEF 14A · Annual proxy (pay & governance)2026-06-04
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Decoy Therapeutics Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.